Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | New buy | 343,037 | $6,545,146 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Added +40% | 27,468 | $524,089 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-04-21 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-15 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-10 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-08 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-01 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-03-16 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.